Helmut Butzkueven
Monash University
H-index: 70
Oceania-Australia
Top articles of Helmut Butzkueven
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Risk of Cervical Abnormalities for Women With Multiple Sclerosis Treated With Moderate-Efficacy and High-Efficacy Disease-Modifying Therapies | Neurology | Francesca Bridge Julia Brotherton Jim Stankovich Paul G Sanfilippo Olga G Skibina | 2024/2/27 |
Use of smartphone-based remote assessments of multiple sclerosis in Floodlight Open, a global, prospective, open-access study | Scientific Reports | Jiwon Oh Luca Capezzuto Lito Kriara Jens Schjodt-Eriksen Johan van Beek | 2024/1/2 |
Big Multiple Sclerosis Data network: an international registry research network | Journal of Neurology | Anna Glaser Helmut Butzkueven Anneke van der Walt Orla Gray Tim Spelman | 2024/4/1 |
The immune cell transcriptome is modulated by vitamin D3 supplementation in people with a first demyelinating event participating in a randomized placebo-controlled trial | Clinical Immunology | Wei Zhen Yeh Melissa Gresle Rodney Lea Bruce Taylor Robyn M Lucas | 2024/5/1 |
The Patient‐Determined Disease Steps scale is not interchangeable with the Expanded Disease Status Scale in mild to moderate multiple sclerosis | European journal of neurology | Yi Chao Foong Daniel Merlo Melissa Gresle Chao Zhu Katherine Buzzard | 2024/1 |
Language impairments in seropositive and seronegative autoimmune encephalitis | Neurological Sciences | Sarah P Griffith Robb Wesselingh Fiore D’Aprano Nabil Seery Tiffany Rushen | 2024/2/15 |
Long-term clinical outcomes in patients with multiple sclerosis who are initiating disease-modifying therapy with natalizumab compared with BRACETD first-line therapies | Therapeutic Advances in Neurological Disorders | Helmut Butzkueven Tomas Kalincik Francesco Patti Mark Slee Bianca Weinstock-Guttman | 2024/1 |
Vitamin D did not reduce multiple sclerosis disease activity after a clinically isolated syndrome | Brain | Helmut Butzkueven Anne-Louise Ponsonby Mark S Stein Robyn M Lucas Deborah Mason | 2024/4 |
Cognitive assessment during the phases of a spontaneous migraine: a prospective cohort study | Neurological Sciences | Jason C Ray David Darby Helmut Butzkueven Manjit S Matharu Elspeth J Hutton | 2024/4/12 |
Monash-Alfred protocol for assessment of atypical parkinsonian syndromes (MAP-APS) | BMJ Neurology Open | Timothy P Siejka Kelly L Bertram Huiliang M Tang Dominic Thyagarajan Terence J O’Brien | 2024 |
The MOG antibody non-P42 epitope is predictive of a relapsing course in MOG antibody-associated disease | Journal of Neurology, Neurosurgery & Psychiatry | Ganesha Liyanage Benjamin P Trewin Joseph A Lopez Jane Andersen Fiona Tea | 2024/1/30 |
No evidence for association between rs10191329 severity locus and longitudinal disease severity in 1813 relapse-onset multiple sclerosis patients from the MSBase registry | Multiple Sclerosis Journal | Maria Pia Campagna Eva Kubala Havrdova Dana Horakova Guillermo Izquierdo Fuencisla Matesanz | 2024/3/21 |
Leukocyte telomere length in multiple sclerosis: relationship between disability severity and pregnancy history | Multiple Sclerosis and Related Disorders | Michael Zhong Sabrina Salberg Sandeep Sampangi Anneke van der Walt Helmut Butzkueven | 2024/4/10 |
Neutropaenia complications from Ocrelizumab and Rituximab treatment | Multiple Sclerosis and Related Disorders | Venus Pang Nabil Seery Robb Wesselingh Wei Yeh Michael Zhong | 2024/1/1 |
Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60 | Journal of Neurology, Neurosurgery & Psychiatry | Yi Chao Foong Daniel Merlo Melissa Gresle Katherine Buzzard Michael Zhong | 2024/3/7 |
Emulating randomised clinical trials in relapsing-remitting multiple sclerosis with non-randomised real-world evidence: an application using data from the MSBase Registry | Journal of Neurology, Neurosurgery & Psychiatry | Alessio Signori Marta Ponzano Tomas Kalincik Serkan Ozakbas Dana Horakova | 2024/1/19 |
Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom | Journal of medical economics | T Spelman WL Herring C Acosta R Hyde VG Jokubaitis | 2024/12/31 |
Comparative effectiveness of natalizumab, fingolimod, and injectable therapies in pediatric-onset multiple sclerosis: A registry-based study | Neurology | Tim Spelman Gabrielle Simoneau Robert Hyde Robert Kuhelj Raed Alroughani | 2024/4/9 |
Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies | Journal of neurology | Ying Li Alice Saul Bruce Taylor Anne-Louise Ponsonby Steve Simpson-Yap | 2024/1 |
Comparative efficacy of ofatumumab versus oral therapies for relapsing multiple sclerosis patients using propensity score analyses and simulated treatment … | Therapeutic Advances in Neurological Disorders | Nicholas Riley Christopher Drudge Morag Nelson Anja Haltner Michael Barnett | 2024/3 |
Co-Authors
